Targeted Prostate Biopsy

Targeted Prostate Biopsy translates suspicious imaging findings into a planned needle location. The clinician uses the identified lesion as the sampling focus, with placement guided cognitively, through MRI-ultrasound fusion, or directly during in-bore MRI guidance. This preserves the connection between the radiologic abnormality and the tissue core collected, allowing the specimen to represent the area that prompted concern.

Targeted sampling focuses tissue collection on a defined lesion, whereas systematic sampling collects tissue from less specifically selected prostate regions. Using the approaches together can provide information from both the suspicious abnormality and broader prostate tissue. This complementary strategy may improve assessment of a lesion while limiting unnecessary cores from areas considered less likely to contain the relevant abnormality.

Multiparametric MRI serves as the main imaging source used to identify suspicious prostate areas before sampling. Its findings establish which lesion should receive focused attention and help define the radiologic target for needle placement. The resulting tissue cores can then be evaluated in relation to that abnormality, supporting characterization of the prostate finding and assessment for clinically significant cancer.

The workflow begins with imaging to identify a suspicious prostate lesion. That finding is then used to plan needle placement, using cognitive targeting, MRI-ultrasound fusion, or in-bore MRI guidance. Clinicians collect tissue cores from the defined target and use the results to characterize the abnormality. The procedure can also be paired with systematic sampling when broader tissue assessment is needed.

These approaches differ in how MRI information guides the needle toward the suspicious lesion. Cognitive targeting uses the clinician's interpretation of the MRI findings during placement, MRI-ultrasound fusion combines MRI information with ultrasound guidance, and in-bore guidance uses MRI during the biopsy itself. All three are targeting strategies, but they apply the imaging information through different guidance arrangements.

The approach is useful when clinicians need tissue information from a specific prostate abnormality identified on imaging. Biopsy results can help detect clinically significant prostate cancer and characterize the finding, while also contributing to treatment planning. Because the sampling is directed toward a defined lesion, it may provide more relevant evidence than collecting unnecessary cores from areas less likely to explain the imaging concern.